Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;8(4):655–667. doi: 10.1111/j.1750-3639.1998.tb00191.x

Survival of Patients with Glioblastoma Multiforme is not Influenced by Altered Expression of P16, P53, EGFR, MDM2 or Bcl‐2 Genes

Elizabeth W Newcomb 1,5,✉, Henry Cohen 2,5, Suzanne R Lee 1, Sandhya K Bhalla 3, Joanna Bloom 1, Roberta L Hayes 4, Douglas C Miller 3,5
PMCID: PMC8098514  PMID: 9804374

Abstract

Deregulated expression of one or more growth control genes including p16, p53, EGF receptor (EGFR), MDM2 or Bcl‐2 may contribute to the treatment resistance phenotype of GBM and generally poor patient survival. Clinically, GBM have been divided into two major groups defined by (1) histologic progression from a low grade tumor (“progressive” or “secondary” GBM) contrasted with (2) those which show initial clinical presentation without a prior history (“de novo” or “primary” GBM). Using molecular genetic analysis for p53 gene mutations together with immunophenotyping for overexpression of EGFR, up to four GBM variants can be distinguished, including the p53+/EGFR progressive or the p53‐/EGFR+ de novo variant. We examined the survival of 80 adult patients diagnosed with astrocytic GBM stratified by age category (>40, 41–60 or 61–80) to determine whether alterations in any one given growth control gene or whether different genetic variants of GBM (progressive versus de novo) were associated with different survival outcomes. Survival testing using Kaplan‐Meier plots for GBM patients with or without altered expression of p16, p53, EGFR, MDM2 or Bcl‐2 showed no significant differences by age group or by gene expression indicating a lack of prognostic value for GBM. Also the clinical outcome among patients with GBM showed no significant differences within each age category for any GBM variant including the progressive and de novo GBM variants indicating similar biologic behavior despite different genotypes. Using a pair‐wise comparison, one‐third of the GBM with normal p16 expression showed accumulation of MDM2 protein and this association approached statistical significance (0.01 < P < 0.05) using the Bonferroni procedure. These GBM may represent a variant in which the p19ARF/MDM2/p53 pathway may be deregulated rather than the p16/cyclin D‐CDK4/Rb pathway.

Full Text

The Full Text of this article is available as a PDF (159.6 KB).

References

  • 1. Burger PC , Green SB ( 1987. ) Patient age, histologic features, and length of survival in patients with glioblastoma multiforme . Cancer 59 : 1617 – 1625 . [DOI] [PubMed] [Google Scholar]
  • 2. Salminen E , Nuutinen JM , Huhtala S ( 1996. ) Multivariate analysis of prognostic factors in 106 patients with malignant glioma . Eur J Cancer 32A : 19181923 . [DOI] [PubMed] [Google Scholar]
  • 3. Iwadate Y , Fujimoto S , Tagawa M , Namba H , Sueyoshi K , Hirose M , Sakiyama S ( 1996. ) Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas . Int J Cancer 69 : 236 – 240 . [DOI] [PubMed] [Google Scholar]
  • 4. Gomez‐Manzano C , Fueyo J , Kyritsis AP , Steck PA , Roth JA , McDonnell TJ , Steck KD , Levin VA , Yung WKA ( 1996. ) Adenovirus‐mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis . Cancer Res 56 : 694 – 699 . [PubMed] [Google Scholar]
  • 5. Weller M , Malipiero U , Aguzzi A , Reed JC , Fontana A ( 1995. ) Protooncogene bcl‐2 gene transfer abrogates Fas/APO‐1 antibody‐mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation . J Clin Invest 95 : 2633 – 2643 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Nagane M , Coufal F , Lin H , Bogler O , Cavenee WK , Huang H‐JS ( 1996. ) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis . Cancer Res 56 : 5079 – 508 . [PubMed] [Google Scholar]
  • 7. Hall PA , Meek D , Lane DP ( 1996. ) p53‐integrating the complexity . J Pathol 180 : 1 – 5 . [DOI] [PubMed] [Google Scholar]
  • 8. Lang FF , Miller DC , Koslow M , Newcomb EW ( 1994. ) Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors . J Neurosurg 81 : 427 – 436 . [DOI] [PubMed] [Google Scholar]
  • 9. Bogler O , Huang HJ , Kleihues P , Cavenee WK ( 1995. ) The p53 gene and its role in human brain tumors . Glia 15 : 308 – 327 . [DOI] [PubMed] [Google Scholar]
  • 10. Ohgaki H , Schauble B , zur Hausen A , von Ammon K , Kleihues P ( 1995. ) Genetic alterations associated with the evolution and progression of astrocytic brain tumors . Vlrchows Arch 427 : 113 – 118 . [DOI] [PubMed] [Google Scholar]
  • 11. von Deimling A , Louis DN , Wiestler OD ( 1995. ) Molecular pathways in the formation of gliomas . Glia 15 : 328 – 338 . [DOI] [PubMed] [Google Scholar]
  • 12. Hayashi Y , Ueki K , Waha A , Wiestler OD , Louis DN , von Deimling A ( 1997. ) Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme . Brain Pathol 7 : 871 – 875 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Newcomb EW , Bhalla SK , Parrish CL , Hayes RL , Cohen H , Miller DC ( 1997. ) bcl‐2 protein expression in astrocytomas in relation to patient survival and p53 gene status . Acta Neuropathol 94 : 369 – 375 . [DOI] [PubMed] [Google Scholar]
  • 14. Scherer HJ ( 1940. ) Cerebral astrocytomas and their derivatives . Am J Cancer 40 : 159 – 198 . [Google Scholar]
  • 15. Dropcho EJ , Soong S‐J ( 1996. ) The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case‐control study . Neurology 47 : 684 – 690 . [DOI] [PubMed] [Google Scholar]
  • 16. Kleihues P , Burger PC , Plate KH , Ohgaki H , Cavenee WK ( 1997. ) Glioblastoma . In : Pathology and Genetics of Tumours of the Nervous System . Kleihues P , Cavenee WK , ( Eds. ), IARC Press; , Lyon , pp 16 – 24 . [Google Scholar]
  • 17. von Deimling A , von Ammon K , Schoenfeld D , Wiestler OD , Seizinger BR , Louis DN ( 1993. ) Subsets of glioblastoma multiforme defined by molecular genetic analysis . Brain Pathol 3 : 19 – 26 . [DOI] [PubMed] [Google Scholar]
  • 18. Van Meyel DJ , Ramsay DA , Casson AG , Keeney M , Chambers AF , Cairncross JG ( 1994. ) p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression . J Natl Cancer Inst 86 : 1011 – 1017 . [DOI] [PubMed] [Google Scholar]
  • 19. Chozick BS , Weicker ME , Pezzullo JC , Jackson CL , Finkelstein SD , Ambler MW , Epstein MH , Finch PW ( 1994. ) Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis . Cancer 73 : 406 – 415 . [DOI] [PubMed] [Google Scholar]
  • 20. Reifenberger J , Ring GU , Gies U , Cobbers JMJL , Oberstrab J , An H‐X , Niederacher D , Wechsler W , Reifenberger G ( 1996. ) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression . J Neuropathol Exp Neurol 7 : 822 – 831 . [DOI] [PubMed] [Google Scholar]
  • 21. Watanabe K , Tachibana O , Sato K , Yonekawa Y , Kleihues P , Ohgaki H ( 1997. ) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas . Brain Pathol 6 : 217 – 224 . [DOI] [PubMed] [Google Scholar]
  • 22. Biernat W , Kleihues P , Yonekawa Y , Ohgaki H ( 1997. ) Amplification and overexpression of MDM2 in primary (de novo) glioblastomas . J Neuropathol Exp Neurol 56 : 180 – 185 . [DOI] [PubMed] [Google Scholar]
  • 23. Louis DN ( 1997. ) A molecular genetic model of astrocytoma histopathology . Brain Pathol 7 : 755 – 764 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. James CD , Carlbom E , Dumanski JP , Hansen M , Nordenskjold M , Collins VP , Cavenee WK ( 1988. ) Clonal genomic alterations in glioma malignancy stages . Cancer Res 48 : 5546 – 5551 . [PubMed] [Google Scholar]
  • 25. von Deimling A , Louis DN , von Ammon K , Petersen I , Hoell T , Chung RY , Martuza RL , Schoenfeld DA , Yasargil MG , Wiestler OD , Seizinger BR ( 1992. ) Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme . J Neurosurg 77 : 295 – 301 . [DOI] [PubMed] [Google Scholar]
  • 26. Barker FG , Davis RL , Chang SM , Prados MD ( 1996. ) Necrosis as a prognostic factor in glioblastoma multiforme . Cancer 77 : 1161 – 1166 . [DOI] [PubMed] [Google Scholar]
  • 27. Jaros E , Perry RH , Adam L , Kelly PJ , Crawford PJ , Kalbag RM , Mendelow AD , Sengupta RP , Pearson ADJ. ( 1992. ) Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki‐67 labelling in brain tumours . Br J Cancer 66 : 373 – 385 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Ganju V , Jenkins RB , O'Fallon JR , Scheithauer BW , Ransom DT , Katzmann JA , Kimmel DW. ( 1994. ) Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers . Cancer 74 : 920 – 927 . [DOI] [PubMed] [Google Scholar]
  • 29. Waha A , Baumann A , Wolf HK , Fimmers R , Neumann J , Kindermann D , Astrahantseff K , Blumcke I , von Deimling A , Schlegel U ( 1996. ) Lack of prognostic relevance of alterations in the epidermal growth factor receptor‐transforming growth factor‐α pathway in human astrocytic gliomas . J Neurosurg 85 : 634 – 641 . [DOI] [PubMed] [Google Scholar]
  • 30. Cunningham JM , Kimmel DW , Scheithauer BW , O'Fallon JR , Novotny PJ , Jenkins RB ( 1997. ) Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value . J Neurosurg 86 : 121 – 130 . [DOI] [PubMed] [Google Scholar]
  • 31. Baxendine‐Jones J , Campbell I , Ellison D ( 1997. ) p53 status has no prognostic significance in glioblastomas treated with radiotherapy . Clinical Neuropathol 16 : 332 – 336 . [PubMed] [Google Scholar]
  • 32. Korkolopoulou P , Christodoulou P , Kouzelis K , Hadjiyannakis M , Priftis A , Stamoulis G , Seretis A , Thomas‐Tsagli E ( 1997. ) MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor . Br J Cancer 75 : 1269 – 1278 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Rainov NG , Dobberstein K‐U , Bahn H , Holzhausen H‐J , Lauten‐schlager C , Heidecke V , Burkert W ( 1997. ) Prognostic factors in malignant glioma: influence of the over‐expression of oncogene and tumor‐suppressor gene products on survival . J Neuro-Oncol 35 : 13 – 28 . [DOI] [PubMed] [Google Scholar]
  • 34. Watanabe K , Sato K , Biernat W , Tachibana O , von Ammon K , Ogata N , Yonekawa Y , Kleihues P , Ohgaki H ( 1997. ) Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies . Clinical Cancer Res 3 : 523 – 530 . [PubMed] [Google Scholar]
  • 35. Kleihues P , Burger PC , Scheithauer BW ( 1993. ) Histological Typing of Tumors of the Central Nervous System . Springer‐Verlag Berlin; , Heidelberg , New York . [Google Scholar]
  • 36. Lang FF , Miller DC , Pisharody S , Koslow M , Newcomb , EW ( 1994. ) High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas . Oncogene 9 : 949 – 954 . [PubMed] [Google Scholar]
  • 37. Newcomb EW , Madonia WJ , Pisharody S , Lang FF , Koslow M , Miller DC ( 1993. ) A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme . Brain Pathol 3 : 229 – 235 . [DOI] [PubMed] [Google Scholar]
  • 38. Rao LS , Miller DC , Newcomb EW ( 1997. ) A correlative immunohistochemistry and molecular genetic study of the inactivation of the p16 INK4 genes in astrocytomas . Diag Mol Pathol 6 : 15 – 122 . [DOI] [PubMed] [Google Scholar]
  • 39. Soong R , Lacopetta BJ ( 1997. ) A rapid and nonisotopic method for screening and sequencing of p53 gene mutations in formalin‐fixed, paraffin‐embedded tumors . Mod Pathol 10 : 252 – 258 . [PubMed] [Google Scholar]
  • 40. Lee , ET ( 1980. ) Statistical Methods for Survival Data Analysis , Lifetime Learning Publication; , Belmont , CA . [Google Scholar]
  • 41. Siegel S , Castellan , Jr. , NJ ( 1988. ) Nonparametric Statistics for the Behavioral Sciences , McGraw Hill; , New York , New York . [Google Scholar]
  • 42. Zar JH ( 1984. ) Biostatistical Analysis , Prentice‐Hall, Inc. , Engelwood Cliffs , NJ . [Google Scholar]
  • 43. Maxwell S and Delaney H. ( 1990. ). Designing Experiments and Analyzing Data , Wadsworth Publishing Co. , Belmont , CA . [Google Scholar]
  • 44. Louis DN , von Deimling A , Chung RY , Rubio M‐P , Whaley JM , Eibl RH , Ohgaki H , Wiestler OD , Thor AD , Seizinger BR ( 1993. ) Comparative study of p53 gene and protein alterations in human astrocytic tumors . J Neuropathol Exp Neurol 52 : 31 – 38 . [DOI] [PubMed] [Google Scholar]
  • 45. Rubio M‐P , von Deimling A , Yandell DW , Wiestler OD , Gusella JF , Louis DN ( 1993. ) Accumulation of wild‐type p53 protein in human astrocytomas . Cancer Res 53 : 3465 – 3467 . [PubMed] [Google Scholar]
  • 46. Koga J , Zhang S , Kumanishi T , Washiyama K , Ichikawa T , Tanaka R , Mukawa J ( 1994. ) Analysis of p53 gene mutations in low‐and high‐grade astrocytomas by polymerase chain reaction‐assisted single‐strand conformation polymorphism and immunohistochemistry . Acta Neuropathol 87 : 225 – 232 . [DOI] [PubMed] [Google Scholar]
  • 47. Rasheed BK , McLendon RE , Herndon JE , Friedman HS , Friedman AH , Bigner DD , Bigner SH ( 1994. ) Alterations of the TP53 gene in human gliomas . Cancer Res 54 : 1324 – 1330 . [PubMed] [Google Scholar]
  • 48. Alderson LM , Castleberg RL , Harsh GR , Louis DN , Henson JW ( 1995. ) Human gliomas with wild‐type p53 express bcl‐2 . Cancer Res 55 : 999 – 1001 . [PubMed] [Google Scholar]
  • 49. Reifenberger G , Liu L , Ichimura K , Schmidt EE , Collins VP ( 1993. ) Amplification and overexpression of MDM2 gene in a subset of human malignant gliomas without p53 mutations . Cancer Res 53 : 2736 – 2739 . [PubMed] [Google Scholar]
  • 50. Biernat W , Tohma Y , Yonekawa Y , Kleihues P , Ohgaki H ( 1997. ) Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas . Acta Neuropathol 94 : 303 – 309 . [DOI] [PubMed] [Google Scholar]
  • 51. Hurtt MR , Moossy J , Donovan‐Peluso M , Locker J ( 1992. ) Amplification of epidermal‐growth‐factor‐receptor gene in gliomas: histopathology and prognosis . J Neuropathol Exp Neurol 51 : 84 – 90 . [DOI] [PubMed] [Google Scholar]
  • 52. Bigner SH , Burger PC , Wong AJ , Werner MH , Hamilton SR , Muhlbaier LH , Vogelstein B , Bigner DD ( 1988. ) Gene amplification in malignant human gliomas: clinical and histopathological aspects . J Neuropathol Exp Neurol 47 : 191 – 203 . [DOI] [PubMed] [Google Scholar]
  • 53. Schlegel J , Merdes A. Stumm G , Albert FK , Forsting M , Hynes N , Kiessling M ( 1994. ) Amplification of the epidermal‐growth‐factor‐receptor‐gene correlates with different growth behaviour in human glioblastoma . Int J Cancer 56 : 72 – 77 . [DOI] [PubMed] [Google Scholar]
  • 54. He J , Allen JR , Collins VP , Allalunis‐Turner MJ , Godbout R , Day RS , James CD ( 1994. ) CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines . Cancer Res 54 : 5804 – 5807 . [PubMed] [Google Scholar]
  • 55. Ueki K , Ono Y , Henson JW , Efird JT , von Deimling A , Louis DN ( 1996. ) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated . Cancer Res 56 : 150 – 153 . [PubMed] [Google Scholar]
  • 56. Burns KL , Ueki K , Jhung SL , Koh J , Louis DN ( 1998. ) Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas . J Neuropathol Exp Neurol 57 : 122 – 130 . [DOI] [PubMed] [Google Scholar]
  • 57. Quelle DE , Zindy F , Ashmun RA , Sherr CJ ( 1995. ) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest . Cell 83 : 993 – 1000 . [DOI] [PubMed] [Google Scholar]
  • 58. Pomerantz J , Schreiber‐Agus N , Liegeois NJ , Silverman A , Alland L , Chin L , Potes J , Chen K , Orlow I , Lee H‐W , Cordon‐Cardo C , DePinho RA ( 1998. ) The Ink4a tumor suppressor gene product, p19Art, interacts with MDM2and neutralizes MDM2′s inhibition of p53 . Cell 92 : 713 – 723 . [DOI] [PubMed] [Google Scholar]
  • 59. Zhang Y , Xiong Y , Yarbrough WG ( 1998. ) ARF promotes MDM2 degradation and stabilizes p53: ARF‐INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways . Cell 92 : 725 – 734 . [DOI] [PubMed] [Google Scholar]
  • 60. Wu X , Bayle H , Olson D , Levine AJ ( 1993. ) The p53‐mdm‐2 autoregulatory feedback loop . Genes & Develop 7 : 1126 – 1132 . [DOI] [PubMed] [Google Scholar]
  • 61. Matsumoto R , Tada M , Nozaki M , Zhang C‐L , Sawamura Y , Abe H ( 1998. ) Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms . Cancer Res 58 : 609 – 613 . [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES